Gone But Not Lost: Implications for Estimating HIV Care Outcomes When Loss to Clinic Is Not Loss to Care.


Journal

Epidemiology (Cambridge, Mass.)
ISSN: 1531-5487
Titre abrégé: Epidemiology
Pays: United States
ID NLM: 9009644

Informations de publication

Date de publication:
07 2020
Historique:
entrez: 3 6 2020
pubmed: 3 6 2020
medline: 18 3 2021
Statut: ppublish

Résumé

In some time-to-event analyses, it is unclear whether loss to follow up should be treated as a censoring event or competing event. Such ambiguity is particularly common in HIV research that uses routinely collected clinical data to report the timing of key milestones along the HIV care continuum. In this setting, loss to follow up may be viewed as a censoring event, under the assumption that patients who are "lost" from a study clinic immediately enroll in care elsewhere, or a competing event, under the assumption that people "lost" are out of care all together. We illustrate an approach to address this ambiguity when estimating the 2-year risk of antiretroviral treatment initiation among 19,506 people living with HIV who enrolled in the IeDEA Central Africa cohort between 2006 and 2017, along with published estimates from tracing studies in Africa. We also assessed the finite sample properties of the proposed approach using simulation experiments. The estimated 2-year risk of treatment initiation was 69% if patients were censored at loss to follow up or 59% if losses to follow up were treated as competing events. Using the proposed approach, we estimated that the 2-year risk of antiretroviral therapy initiation was 62% (95% confidence interval: 61, 62). The proposed approach had little bias and appropriate confidence interval coverage under scenarios examined in the simulation experiments. The proposed approach relaxes the assumptions inherent in treating loss to follow up as a censoring or competing event in clinical HIV cohort studies.

Sections du résumé

BACKGROUND
In some time-to-event analyses, it is unclear whether loss to follow up should be treated as a censoring event or competing event. Such ambiguity is particularly common in HIV research that uses routinely collected clinical data to report the timing of key milestones along the HIV care continuum. In this setting, loss to follow up may be viewed as a censoring event, under the assumption that patients who are "lost" from a study clinic immediately enroll in care elsewhere, or a competing event, under the assumption that people "lost" are out of care all together.
METHODS
We illustrate an approach to address this ambiguity when estimating the 2-year risk of antiretroviral treatment initiation among 19,506 people living with HIV who enrolled in the IeDEA Central Africa cohort between 2006 and 2017, along with published estimates from tracing studies in Africa. We also assessed the finite sample properties of the proposed approach using simulation experiments.
RESULTS
The estimated 2-year risk of treatment initiation was 69% if patients were censored at loss to follow up or 59% if losses to follow up were treated as competing events. Using the proposed approach, we estimated that the 2-year risk of antiretroviral therapy initiation was 62% (95% confidence interval: 61, 62). The proposed approach had little bias and appropriate confidence interval coverage under scenarios examined in the simulation experiments.
CONCLUSIONS
The proposed approach relaxes the assumptions inherent in treating loss to follow up as a censoring or competing event in clinical HIV cohort studies.

Identifiants

pubmed: 32483067
doi: 10.1097/EDE.0000000000001201
pii: 00001648-202007000-00014
pmc: PMC8344105
mid: NIHMS1724438
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

570-577

Subventions

Organisme : NIAID NIH HHS
ID : K01 AI125087
Pays : United States
Organisme : FIC NIH HHS
ID : K01 TW010272
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI096299
Pays : United States

Références

Am J Epidemiol. 2018 Mar 1;187(3):623-632
pubmed: 29020256
Epidemiology. 2003 Nov;14(6):680-6
pubmed: 14569183
Am J Epidemiol. 2018 Aug 1;187(8):1808-1816
pubmed: 29420696
Stat Med. 2014 Jan 15;33(1):129-42
pubmed: 23873614
Am J Epidemiol. 2017 Oct 15;186(8):1010-1014
pubmed: 28535275
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S228-32
pubmed: 23764640
AIDS Care. 2016 Nov;28(11):1386-93
pubmed: 27145451
Clin Infect Dis. 2018 Nov 13;67(11):1643-1652
pubmed: 29889240
Am J Epidemiol. 2015 Feb 15;181(4):246-50
pubmed: 25660080
PLoS One. 2017 Jan 12;12(1):e0169871
pubmed: 28081230
Am Stat. 2001;55(3):207-210
pubmed: 28845048
Int J Epidemiol. 2012 Jun;41(3):861-70
pubmed: 22253319
BMJ Open. 2018 Apr 20;8(4):e017487
pubmed: 29678963
PLoS Med. 2018 Jan 12;15(1):e1002489
pubmed: 29329301
Curr Epidemiol Rep. 2016 Dec;3(4):285-296
pubmed: 28824834
Am J Epidemiol. 2019 Apr 1;188(4):632-636
pubmed: 30698633
PLoS Med. 2011 Oct;8(10):e1001111
pubmed: 22039357
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Am J Epidemiol. 2010 Jul 1;172(1):107-15
pubmed: 20547574
Epidemiology. 2019 Nov;30(6):817-824
pubmed: 31393316
AIDS Res Hum Retroviruses. 2007 Jun;23(6):769-76
pubmed: 17604539
PLoS One. 2015 Sep 02;10(9):e0137454
pubmed: 26331616
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Epidemiology. 2016 Jan;27(1):91-7
pubmed: 26484424
Int J Epidemiol. 2015 Aug;44(4):1452-9
pubmed: 25921223
Clin Infect Dis. 2016 Apr 1;62(7):935-944
pubmed: 26679625
J Int AIDS Soc. 2018 Nov;21(11):e25196
pubmed: 30489698
PLoS One. 2018 Apr 2;13(4):e0195231
pubmed: 29608618
PLoS Med. 2011 Jan 18;8(1):e1000390
pubmed: 21267057

Auteurs

Jessie K Edwards (JK)

From the Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Catherine R Lesko (CR)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Michael E Herce (ME)

Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.

Gad Murenzi (G)

Rwanda Military Hospital, Kigali, Rwanda.

Christella Twizere (C)

Centre Hospitalo, Universitaire de Kamenge, Bujumbura, Burundi.

Patricia Lelo (P)

Kalembelembe Pediatric Hospital, Kinshasa, Democratic Republic of the Congo.

Kathryn Anastos (K)

Departments of Medicine and Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY.

Olga Tymejczyk (O)

Institute for Implementation Science in Population Health, City University of New York, New York, NY.

Marcel Yotebieng (M)

Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY.

Denis Nash (D)

Institute for Implementation Science in Population Health, City University of New York, New York, NY.

Adebola Adedimeji (A)

Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY.

Andrew Edmonds (A)

From the Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH